La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
CD73: a novel checkpoint protein STUTTGART, Germany I September 08, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active CD73 inhibitors in R&D: Pipeline of CD73 Inhibitors. This competitive intelligence report
IGF-1R: a validated thyroid eye disease target and a re-emerging cancer target – a pipeline review STUTTGART, Germany I September 05, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-IGF-1(R)
NaPi2b: a viable solid tumor target for novel ADC technologies – a pipeline review STUTTGART, Germany I September 04, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-NaPi2b immunotherapies in
FcRn: a commercially and clinically validated target in a variety of antibody-mediated autoimmune diseases – a pipeline review STUTTGART, Germany I September 03, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of
New service: competitor analysis of targeted immunotherapies with targets selected by clients STUTTGART, Germany I September 01, 2025 I La Merie Publishing announced the launch of its newest service offering of reviewing the pipeline of immunotherapeutics for targets selected by
KLK2: promising drug target in prostate cancer – a pipeline review STUTTGART, Germany I August 31, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-KLK2 immunotherapeutics in R&D: Pipeline of
Vectorized antibodies by in vivo expression of DNA or RNA overcome limitations of systemically administered antibodies STUTTGART, Germany I August 30, 2025 I Antibodies as a drug modality in general have become extremely successful in terms of clinically effective therapies
STEAP1 and STEAP2: emerging prostate cancer targets – a pipeline review STUTTGART, Germany I August 30, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-STEAP1- and/or STEAP2 immunotherapeutics in R&D:
Tissue Factor: a validated target for improved solid tumor antibody-drug conjugates – a pipeline review STUTTGART, Germany I August 27, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Tissue Factor
CD38: a Blockbuster sales target under fire by biosuperior and biosmilar antibody competitors – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active
